By Condition

Sofos-Daclit Tablets combine Sofosbuvir 400 mg and Daclatasvir 60 mg in a single oral tablet, forming a potent direct-acting antiviral (DAA) regimen for Chronic Hepatitis C Virus (HCV) infection. This combination works synergistically to block viral replication and assembly, leading to high sustained virologic response (SVR) rates—typically above 95% across major genotypes.

Physicians prescribe Sofos-Daclit as part of a once-daily, interferon-free treatment plan over 12 to 24 weeks, depending on the patient’s HCV genotype, liver fibrosis stage, and prior treatment history. The all-pill regimen improves patient compliance compared to older injectable options.

Each tablet contains the fixed-dose components that ease dosing logistics and support consistent plasma levels when taken with or without food. Common side effects are mild and include headache, fatigue, nausea, and insomnia.

Take one Sofos-Daclit tablet daily at the same time to maintain steady drug levels. Regular follow-up through blood tests and liver function checks helps confirm treatment success and ensure safety.

Store the tablets below 30 °C in a dry place, away from direct sunlight and out of children’s reach for optimal stability.